<DOC>
	<DOCNO>NCT02919449</DOCNO>
	<brief_summary>This Phase 1 study design determine maximum tolerate dose ( MTD ) toxicity attenuate Measles virus ( MV-NIS ) combine nivolumab patient recurrent metastatic ( NSCLC ) .</brief_summary>
	<brief_title>Trial Measles Virotherapy Combination With Nivolumab Patients With Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Diagnosis metastatic lung cancer , histologic confirmation primary NSCLC histology least one lesion amenable intratumoral injection MVNIS . Patient meet FDAapproved indication nivolumab treatment NSCLC . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 . Ability provide inform consent . Adequate hematological , liver kidney function . Must willing implement contraception throughout study 8 week follow last study drug administration . Key Any follow prior therapy : Chemotherapy ≤ 3 week prior registration . Biologic therapy ≤ 4 week prior registration . Radiation therapy ≤ 3 week prior registration Other concurrent investigational therapy ( utilized nonFDAapproved indication context research investigation ) . Pregnant woman . Nursing woman . Men woman childbearing potential unwilling employ adequate contraception treatment 8 week follow completion study drug treatment . Allergy measles vaccine history severe reaction prior measles vaccination . History organ transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Lung Cancer Measles Nivolumab Opdivo</keyword>
</DOC>